Forest Laboratories received approval from the FDA for its sNDA for Lexapro for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, ages 12 to 17. Lexapro is the second antidepressant to be approved for the treatment of MDD in adolescents. The approval was supported by two placebo-controlled studies, one conducted in adolescent patients taking Lexapro and one conducted in children and adolescents taking citalopram. In an eight-week study that compared Lexapr...